Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
Large B-Cell Diffuse Lymphoma
DRUG: Oral azacitidine|DRUG: R-ICE
Presence or absence of a dose limiting toxicity in the combination of oral azacitidine and R-ICE, A 3+3 dose-escalation design will be used to determine the recommended phase II dose., 126 days
Response rate, Overall response rate is the rate of complete response plus partial response. It will be assessed by the IWG 2014 response criteria for NHL and the Deuville Criteria for scan interpretation., While on study, between day 56 and day 70|progression free survival, From start of treatment to time of documented progression or date of death, whichever occurs first, assessed up to 1 year.|Adequate peripheral stem cell collection, This will be assessed by the number of stem cells collection prior to ASCT. Adequate collection is considered to be at least 2,000,000 CD34+ stem cells per kilogram., At the time of ASCT (10 weeks after start of study therapy)
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.